Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting cancer homing into the lymph node with a novel anti-CCR7 therapeutic antibody: the paradigm of CLL

Published:2021-01-01 Issue:1 Volume:13 Page:
ISSN:1942-0862
Container-title:mAbs
language:en
Short-container-title:mAbs

Author:

Cuesta-Mateos Carlos¹²³,Juárez-Sánchez Raquel¹³,Mateu-Albero Tamara³,Loscertales Javier⁴,Mol Wim²⁵,Terrón Fernando¹²,Muñoz-Calleja Cecilia³⁶

Affiliation:

1. Immed S.L., Immunological and Medicinal Products, Madrid, Spain

2. Catapult Therapeutics, Lelystad, The Netherlands

3. Immunology Department, Hospital Universitario De La Princesa, IIS-IP, Madrid, Spain

4. Hematology Department, Hospital Universitario De La Princesa, IIS-IP, Madrid, Spain

5. Pepscan, Lelystad, The Netherlands

6. Medicine Faculty, Universidad Autónoma De Madrid, Madrid, Spain

Publisher

Informa UK Limited

Subject

Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/19420862.2021.1917484

Reference61 articles.

1. Tumor-induced stromal reprogramming drives lymph node transformation

2. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL

3. Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia

4. How the microenvironment wires the natural history of chronic lymphocytic leukemia

5. CCR7 Coordinates the Primary Immune Response by Establishing Functional Microenvironments in Secondary Lymphoid Organs

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. S. mansoni -derived omega-1 prevents OVA-specific allergic airway inflammation via hampering of cDC2 migration;PLOS Pathogens;2024-08-26

2. Proliferating CLL cells express high levels of CXCR4 and CD5;2023-12-27

3. Evaluation of the novel therapeutic anti‐CCR7 antibody CAP‐100 as an add‐on therapy in chronic lymphocytic leukemia patients receiving venetoclax;Hematological Oncology;2023-08-07

4. Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma;Science Translational Medicine;2023-06-28

5. Recent Emerging Immunological Treatments for Primary Brain Tumors: Focus on Chemokine-Targeting Immunotherapies;Cells;2023-03-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3